{"ticker": {"uuid": "c16336be-f2ea-4987-97eb-a31161c9d2de", "symbol": "NPCE", "name": "Neuropace Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Medical Devices"}, "articles": [{"title": "Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now", "summary": "NeuroPace (NPCE) stock is recommended for retention due to anticipated growth from its RNS System adoption, expanding referral networks, and AI innovations, with potential long-term benefits from an IGE indication. However, profitability may face near-term pressure from increased", "url": "https://www.tradingview.com/news/zacks:6723c9519094b:0-here-s-why-you-should-retain-neuropace-stock-in-your-portfolio-for-now/", "source_name": "TradingView", "published_at": "2026-07-15T14:13:13", "published_display": "15 Jul 2026 14:13", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Reflecting On Medical Devices & Supplies - Specialty Stocks\u2019 Q1 Earnings: Integer Holdings (NYSE:ITGR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNUFd1SUpRcWlCdEFjU1YzNTZkdjBfRkwyY2lBYjh1ZXZlZTlyVlpWSWx1bExvckFrNHNhUEdVTGNFWUxaMkVDZUV2c2hPS1h2YVhNSHNsVzFYNUFrNHBnRVM1STRsa2Zmb0VXeEQ4UFRGNDBOWXZfWVU5VFUyQ3JZZm9KamZMWXVDSEtNMWwyVktpaEZfRjVNU1BYaWJ3NnpNUmRyMEpsSzBXdw?oc=5", "source_name": "Market source", "published_at": "2026-07-14T18:07:11+00:00", "published_display": "14 Jul 2026 18:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "NeuroPace (NASDAQ:NPCE) Shares Down 5.8% - What's Next?", "summary": "NeuroPace (NASDAQ:NPCE) shares dropped 5.8% on Tuesday, trading as low as $16.23 on significantly below-average volume. Despite beating recent quarterly earnings and revenue expectations, the company reported negative margins and has a high debt-to-equity ratio of 4.08. Analyst s", "url": "https://www.marketbeat.com/instant-alerts/neuropace-nasdaqnpce-shares-down-58-whats-next-2026-07-14/", "source_name": "MarketBeat", "published_at": "2026-07-14T18:13:10", "published_display": "14 Jul 2026 18:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroPace (NPCE) Proxy filing Summary", "summary": "NeuroPace (NPCE) has scheduled its Annual Meeting for June 5, 2026, to be held virtually, where stockholders of record as of April 9, 2026, will vote on the election of two Class II directors, Lisa Andrade and Scott Huennekens, and the ratification of PricewaterhouseCoopers LLP a", "url": "https://quartr.com/events/neuropace-npce-proxy-filing_ofSSALdK", "source_name": "Quartr", "published_at": "2026-07-10T22:40:39", "published_display": "10 Jul 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroPace, Inc. (NASDAQ:NPCE) Given Consensus Recommendation of \"Moderate Buy\" by Brokerages", "summary": "NeuroPace, Inc. (NASDAQ:NPCE) has received a \"Moderate Buy\" consensus rating from eight analysts, with an average 12-month price target of $18.83. The company recently surpassed quarterly earnings estimates, reporting an EPS of -$0.13 against an expected -$0.19 and revenue slight", "url": "https://www.marketbeat.com/instant-alerts/neuropace-inc-nasdaqnpce-given-consensus-recommendation-of-moderate-buy-by-brokerages-2026-07-10/", "source_name": "MarketBeat", "published_at": "2026-07-10T08:39:39", "published_display": "10 Jul 2026 08:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroPace (NASDAQ:NPCE) Stock Price Up 1.1% - What's Next?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxPSE9ZN18wUDkyTWRWdmZIaldqdjNWYzJucE1ZTE5teGZLSkRUUEF6c2hqOEZWcG1sU3FPSDRfMjFKM2dnaFZIS04wdXBLOEVpMmNqQ01Cek1JSTRIUjB5QWF3VHBlSkZ0Uzdvb2N6YXhCWlhlS3JVa0lMWmpKT2QyU0xRZ0RuX0R3Rm9JTGh4NlU4ajgybEljNk5kNjhPZWd1bFdTQ013?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-10T05:02:47+00:00", "published_display": "10 Jul 2026 05:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "At US$17.80, Is It Time To Put NeuroPace, Inc. (NASDAQ:NPCE) On Your Watch List?", "summary": "NeuroPace, Inc. (NASDAQ:NPCE) has seen a significant share price rise of 39% recently but is currently trading at US$17.80, which is 27% overvalued compared to its intrinsic value of $14.05. Despite this, the company's future outlook appears bright with expected profit growth of ", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-npce/neuropace/news/at-us1780-is-it-time-to-put-neuropace-inc-nasdaqnpce-on-your", "source_name": "Simply Wall Street", "published_at": "2026-07-08T10:11:55", "published_display": "08 Jul 2026 10:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Neuropace, Inc. \u2013 NASDAQ:NPCE", "summary": "This article provides financial information for Neuropace, Inc. (NASDAQ:NPCE), specifically focusing on its forward price-to-earnings ratio. It seems to be a financial data page from TradingView, which lists various financial metrics and resources related to the company. The cont", "url": "https://www.tradingview.com/symbols/NASDAQ-NPCE/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T04:39:18", "published_display": "04 Jul 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NPCE - NeuroPace Inc Short Interest", "summary": "This article provides detailed financial and stock performance data for NeuroPace Inc (NPCE). It covers various metrics including short interest, market capitalization, income, sales, P/E ratios, insider and institutional ownership, and year-over-year growth figures. The data als", "url": "https://finviz.com/stock?t=NPCE&ty=si&ta=1&p=d", "source_name": "Finviz", "published_at": "2026-07-03T08:11:39", "published_display": "03 Jul 2026 08:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NPCE - NeuroPace Inc Website Traffic and Mobile Apps Usage", "summary": "This article provides a comprehensive overview of NeuroPace Inc. (NPCE), a medical device company specializing in epilepsy treatments. It details the company's financial metrics, stock performance, analyst recommendations, and a chronological list of significant news and events, ", "url": "https://finviz.com/stock?t=NPCE&ty=tr", "source_name": "Finviz", "published_at": "2026-07-03T04:39:18", "published_display": "03 Jul 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroPace | 4: Statement of changes in beneficial ownership of securities-Director Fischer Frank M", "summary": "This article announces a statement of changes in beneficial ownership of securities for Director Fischer Frank M at NeuroPace (NPCE), as filed with the SEC on June 6. It also includes extensive disclaimers from Moomoo regarding the informational nature of the content and the risk", "url": "https://www.moomoo.com/news/notice/307480082/neuropace-4-statement-of-changes-in-beneficial-ownership-of-securities", "source_name": "Moomoo", "published_at": "2026-07-02T04:39:18", "published_display": "02 Jul 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price-Driven Insight from (NPCE) for Rule-Based Strategy", "summary": "This article provides a price-driven analysis of Neuropace Inc. (NPCE) using AI models to determine trading strategies. It highlights a strong near-term sentiment that could lead to a neutral mid-term and positive long-term bias, and outlines specific institutional trading strate", "url": "https://news.stocktradersdaily.com/news_release/11/Price-Driven_Insight_from_NPCE_for_Rule-Based_Strategy_062826121803_1782620283.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-28T00:10:14", "published_display": "28 Jun 2026 00:10", "sentiment": "positive", "sentiment_pct": 68, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroPace, Inc. (NPCE) Reveals FDA Approval of ECoG Assistant\u2122", "summary": "NeuroPace, Inc. (NASDAQ:NPCE) announced FDA approval for its ECoG Assistant\u2122, an AI-driven tool designed to enhance epilepsy care by analyzing long-term intracranial EEG data. The technology, built on extensive epileptologist-labeled records, aims to improve efficiency in data re", "url": "https://www.insidermonkey.com/blog/neuropace-inc-npce-reveals-fda-approval-of-ecog-assistant-1790336/", "source_name": "Insider Monkey", "published_at": "2026-06-27T11:31:00", "published_display": "27 Jun 2026 11:31", "sentiment": "positive", "sentiment_pct": 90, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroPace, Inc. Actuals & Estimates (NASDAQ:NPCE)", "summary": "This article provides an overview of NeuroPace, Inc. (NASDAQ: NPCE) stock, including its current price, market capitalization, historical highs and lows, and analyst forecasts. It also details recent financial performance, such as earnings per share and revenue for past quarters,", "url": "https://www.tradingview.com/symbols/NASDAQ-NPCE/forecast-actuals-and-estimates/?category=cash_flow", "source_name": "TradingView", "published_at": "2026-06-26T02:09:55", "published_display": "26 Jun 2026 02:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroPace (NPCE) CMO has shares withheld to cover RSU tax bill", "summary": "NeuroPace Inc.'s Chief Medical Officer, Martha Morrell, had 335 shares of common stock withheld on June 24, 2026, to cover tax obligations related to a restricted stock unit vesting. These shares were disposed of at $16.22 per share. Following this transaction, Morrell directly h", "url": "https://www.stocktitan.net/sec-filings/NPCE/form-4-neuro-pace-inc-insider-trading-activity-5979203ed972.html", "source_name": "Stock Titan", "published_at": "2026-06-25T20:09:21", "published_display": "25 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NPCE Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides an overview of Neuropace, Inc. (NPCE) stock, including its current price, analyst forecasts, and recent financial performance. It highlights that 8 analysts offer 1-year price targets, with a max estimate of $22.00 and a min estimate of $18.00. The company's", "url": "https://www.tradingview.com/symbols/NASDAQ-NPCE/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T17:09:22", "published_display": "25 Jun 2026 17:09", "sentiment": "positive", "sentiment_pct": 63, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Neuropace Inc For: 22 June By Investing.com", "summary": "This article provides details about a Form 4 filing for Neuropace Inc. on June 22 and mentions the company's stock symbol NPCE, which saw a slight decrease. It is a very brief report, likely indicating an insider transaction or change in ownership, without providing further speci", "url": "https://ng.investing.com/news/stock-market-news/form-4-neuropace-inc-for-22-june-93CH-2568689", "source_name": "Investing.com Nigeria", "published_at": "2026-06-22T21:38:00", "published_display": "22 Jun 2026 21:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroPace (NPCE) director granted 789 shares as quarterly fee award", "summary": "NeuroPace director Uri Geiger was awarded 789 shares of common stock at $15.63 per share as a quarterly fee, in lieu of a cash retainer, under the company's non-employee director compensation policy. Following this award, Geiger directly holds 18,537 NeuroPace shares, with an add", "url": "https://www.stocktitan.net/sec-filings/NPCE/form-4-neuro-pace-inc-insider-trading-activity-725f3038cc28.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:39:33", "published_display": "22 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroPace (NPCE) director Rakhi Kumar awarded 989 shares as quarterly retainer", "summary": "NeuroPace Inc. director Rakhi Kumar was granted 989 common shares as a quarterly retainer, valued at $15.63 per share. This stock award is part of the company's non-employee director compensation policy and increases Kumar's direct holdings to 23,039 NeuroPace common shares. The ", "url": "https://www.stocktitan.net/sec-filings/NPCE/form-4-neuro-pace-inc-insider-trading-activity-11875424d20a.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:39:33", "published_display": "22 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] NeuroPace Inc Insider Trading Activity", "summary": "NeuroPace Inc. director Frank M. Fischer reported the acquisition of 1,467 shares of Common Stock on June 19, 2026, as detailed in a recent Form 4 filing. These shares were awarded as part of the company's non-employee director compensation policy, given in lieu of quarterly cash", "url": "https://www.stocktitan.net/sec-filings/NPCE/form-4-neuro-pace-inc-insider-trading-activity-d4f63e662224.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:39:33", "published_display": "22 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroPace, Inc.(NasdaqGM:NPCE) added to S&P Healthcare Equipment Select Industry Index", "summary": "NeuroPace, Inc. (NasdaqGM:NPCE), a medical device company specializing in epilepsy treatment, has been added to the S&P Healthcare Equipment Select Industry Index. This news follows recent company updates, including FDA approval for its ECoG Assistant and the submission of a next", "url": "https://www.marketscreener.com/news/neuropace-inc-nasdaqgm-npce-added-to-s-p-healthcare-equipment-select-industry-index-ce7f5cd3d88afe21", "source_name": "www.marketscreener.com", "published_at": "2026-06-22T01:10:38", "published_display": "22 Jun 2026 01:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuropace Inc (NPCE) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Neuropace Inc (NPCE) has a weak financial health score of 6.53, ranking 150 out of 203 in its industry, with average operating efficiency. Its latest quarterly revenue saw a 2.02% year-over-year decrease to $22.07 million, and net profit also fell by 1.52% year-over-year. Key fin", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-npce/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T10:39:25", "published_display": "18 Jun 2026 10:39", "sentiment": "negative", "sentiment_pct": 30, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuropace Inc (NPCE) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Neuropace Inc (NPCE), detailing its price momentum score of 6.58 and its current trading range between a resistance level of $16.91 and a support level of $14.14. It examines various technical indicators, such as MACD, RSI, and moving", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-npce/technical", "source_name": "TradingKey", "published_at": "2026-06-18T03:40:13", "published_display": "18 Jun 2026 03:40", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuropace Inc (NPCE) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Neuropace Inc (NPCE), noting its current valuation score is 9.40, ranking 21st in its industry. It highlights the company's P/E ratio of -23.50, which is significantly below its recent high. The report also states that relevant P/B, P", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-npce/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T02:40:50", "published_display": "18 Jun 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuropace Inc (NPCE) Institutional Confidence", "summary": "Neuropace Inc (NPCE) has an institutional shareholding score of 10.00, placing it first in the Healthcare Equipment & Supplies industry. Institutional investors hold 99.26% of shares, a 7.21% increase quarter-over-quarter. James Simons is the largest institutional shareholder, ho", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-npce/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T02:40:13", "published_display": "18 Jun 2026 02:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuropace Inc (NPCE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article focuses on the revenue breakdown for NeuroPace Inc (NPCE), indicating that relevant data for business segments and regional profit contributions have not yet been disclosed by the company. It briefly presents the company's United States revenue at $99.99 million with", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-npce/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T01:40:13", "published_display": "18 Jun 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(NPCE) Price Dynamics and Execution-Aware Positioning", "summary": "This article analyzes Neuropace Inc. (NPCE) stock dynamics, highlighting weak near and mid-term sentiment but a strong long-term outlook. It presents AI-generated trading strategies including position trading, momentum breakout, and risk hedging, with specific entry points, targe", "url": "https://news.stocktradersdaily.com/news_release/12/NPCE_Price_Dynamics_and_Execution-Aware_Positioning_061626110601_1781665561.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-16T23:10:59", "published_display": "16 Jun 2026 23:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuropace Inc (NPCE) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Neuropace Inc (NPCE), highlighting its current earnings forecast score of 8.50 and an average analyst price target of $18.00. Analysts largely recommend a \"Buy\" for NPCE, with expectations for future revenue and EPS also detailed. Th", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-npce/earnings", "source_name": "TradingKey", "published_at": "2026-06-16T22:10:32", "published_display": "16 Jun 2026 22:10", "sentiment": "positive", "sentiment_pct": 68, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroPace (NPCE) down 0.6% since last earnings report: Can it rebound?", "summary": "This article discusses the recent performance of NeuroPace (NPCE) stock, which has dropped 0.6% since its last earnings report. It raises the question of whether the stock can rebound from this decline. The content of the article would likely delve into factors influencing NPCE's", "url": "https://www.msn.com/en-us/money/topstocks/neuropace-npce-down-0-6-since-last-earnings-report-can-it-rebound/ar-AA25p2rH", "source_name": "MSN", "published_at": "2026-06-15T16:39:39", "published_display": "15 Jun 2026 16:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts Believe NeuroPace (NPCE) Could Rally 27.88%: Here's is How to Trade", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/wall-street-analysts-believe-neuropace-135503665.html", "source_name": "Zacks", "published_at": "2026-06-15T13:55:03+00:00", "published_display": "15 Jun 2026 13:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroPace Inc RNS System gains favor for targeted seizure interruption", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxNNmREdzhmckdRMVJWYldMVGlyZlM5U2pMYkxFZHhNV2RDck9lWGt0cDdJbUlqZFJjWER2TDMwbDJmM05PbzE5NnBWb0MwakdYTnVEdXprNXFJV21ySlhwRm9yQ0lqZ19YMVdnUlVDZlM5MUd3Wm1YcU5lV1Y3UmlUak5IbEM?oc=5", "source_name": "Traders Union", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks Q1 Earnings: ICU Medical (NASDAQ:ICUI) Firing on All Cylinders", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAJBVV95cUxQLWl0NWl5MFJhUXFSN0pzSW1sVzJVb21XVml0X0doQnd5eDVUQmVqeFZWSmNmdlZaV2pfbFk3UEl3RXlqZ05pckozR0dnNHNEUlpTa2FPYWc1Z3Q0Y2tXYTljZUlQRkVZNzY2Sl9yRksyUDJkNVQzSTBuLW9uMnI5bzBfTTJGdDUzd25DN3dDSmhwWnpGVXZRVVM2Uy1zMnp4STZ1RGdZZkRpZ21Pb2xtWjRSTk1kc2JrT28wTG81NDV1M2tWaVdrOXBQdVZSTExiTVEzMXpqRnJWWi0xcEdMYVFILXZXbXZVZl9GRm12aTl5OGk4X1dSVjVyU2FIVFpubk1YNm5fQll0MVZqRTZpTA?oc=5", "source_name": "StockStory", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Here's Why You Should Add NeuroPace Stock to Your Portfolio Now", "summary": "NeuroPace, Inc. (NPCE) is poised for significant growth, driven by the strong adoption of its RNS System, expanding referral networks, and AI-driven innovations aimed at improving efficiency in epilepsy treatment. The potential FDA approval for idiopathic generalized epilepsy (IG", "url": "https://www.tradingview.com/news/zacks:1b6ea4907094b:0-here-s-why-you-should-add-neuropace-stock-to-your-portfolio-now/", "source_name": "TradingView", "published_at": "2026-06-10T14:39:03", "published_display": "10 Jun 2026 14:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroPace, Inc. Files Form 8-K Reporting 2026 Annual Meeting Results and Company Information", "summary": "NeuroPace, Inc. filed Form 8-K to report the results of its 2026 Annual Meeting, held virtually on June 5, 2026. Shareholders re-elected two Class II directors and ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm, showing strong support for", "url": "https://www.minichart.com.sg/2026/06/09/neuropace-inc-files-form-8-k-reporting-2026-annual-meeting-results-and-company-information/", "source_name": "Minichart", "published_at": "2026-06-09T17:49:42", "published_display": "09 Jun 2026 17:49", "sentiment": "positive", "sentiment_pct": 60, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The NeuroPace (NPCE) Investment Story Is Shifting Without A New Analyst Price Target", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQVXBlemUxQm5vTlJCQ28xNFZNRTZpZDNPMmFNbXpPTTBFNGFoak1JQUFybUtQMnF4MFBIU1VDMDZ3NFljbHJjUHNfX1lsV3lkSHhVbGhuanRNbzdlckNRODhwLTFiOGpuMDZsYzNockR1cGxiejdGZEhuMm9RT3dBcWlfbldiZ1RSVHZHYy1udDA2emlRRTBzOU5JY2N3NmcySmlqUm9yUFU?oc=5", "source_name": "Market source", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroPace Says US FDA Approves ECoG Assistant for Improving Epilepsy Outcomes", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/neuropace-says-us-fda-approves-124357999.html", "source_name": "MT Newswires", "published_at": "2026-05-29T12:43:57+00:00", "published_display": "29 May 2026 12:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NPCE Explains How NeuroPace's RNS System Makes Money", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxONGlfX0dLM2RwM3JGcHpSYV9lUUxDemVmT1lCWFRQbE52U0RUWEFnZ3ZoZHdyemszeFZ1dzJvekZZNFJESG5wQTJRUHd1MmJVNVZDZnMwZ0NKdlVia0R0clJZWUk1Vll0ZWdzd3lvRW5oQ09nbjNVOGd5a0lPX2M4YlZxaE5hc0c1ZklGU2MzTF9FNXdPbTh6ZlJXSmRCV1FLYU9zeWNQZw?oc=5", "source_name": "Market source", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroPace NPCE and the Next Wave of AI-Driven Epilepsy Care", "summary": "", "url": "https://news.google.com/rss/articles/CBMif0FVX3lxTFBDWE9XVi1KdlJpVzIzU0gzWGgyc1hLWDhTQlJybmpyWXpFTFFBLUVJbjk3R0QyM1o2VWxnYUxoc1BJTnhhcmZrQlRSS0RTdEo0R2NvWUJLZ1JxWG9GX1BRNlg4d3FaRER1dV90SWtDQ0lXU2FhWDNUb2thbXB0TDg?oc=5", "source_name": "qz.com", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Review: Medical Devices & Supplies - Diversified Stocks Led by Baxter (NYSE:BAX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNYjhBT3BjMWFVU1FFUUFub0d6QUVEUTdwWFVMRG5fN2dHSnIxTXQwMWU1aElKaEV1a2dYLTFHMlBzMVFTZEtaX0xRRDFhZDl1WFdDYWF2RDZxOG9SRUtycmZacTRzM2FaaEU3OS1GZ2taLWtSMjZ4enhVNHRvdzJsanp4cEhNcGI1dllTOUplWUUtNjRlRm85MlFEVWxSYUV2d243QVd3?oc=5", "source_name": "Market source", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "NeuroPace, Inc. (NASDAQ:NPCE) First-Quarter Results: Here's What Analysts Are Forecasting For This Year", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQamNzQTM2WlNEaVBlNnpNZUsyM3hQWGVyWnhhR1hZbU80ek04SU5PYlI2clNQOGJnZ05LZGNXenZEV3puT2FPT0otdko4eExiblQ5YVhQZy1ETDRVQW53Vks0TzRIakxMc2ZKVVZINFI5dDRnbkkzRzRrdFFrRkttTGFYd1E5MkQyMTRBTE9pYWVDQy1wdkg0WVNPdk8?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroPace (NPCE) Moves 6.3% Higher: Will This Strength Last?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiekFVX3lxTE9aR2d1NUY1UWJDdzNaeFJLMld3N19ZNDRwN01rZ3hNRFdXOGNVYlg5cFhXSFQtRzBLdmZQQThCZXUyTmduLXBfSF9IelN4ZHAydEFDelQ5WWlWdElpd3ZqVUQzbW9pd1ZUMTEwLTZDWnRBQmVLNXJQS25R?oc=5", "source_name": "qz.com", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Medical Devices & Supplies - Specialty Q4 Earnings: Globus Medical (NYSE:GMED) is the Best in the Biz", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNcDFMNmtOVk5PVFM1YzMyVWhyS3dwY0dMVE5BUng5U1JoOFRQMXNFRGxTMmlBRUV0bENRSWFXTDFZOXBQQkNZT0FOWDdISjRCcU9pRV9aNHBwUVBuZkVEV3g1dklVY19KOE9iWUNpNUtMS2NuOEcxMlQtNU8ydURybEdkNVoxZThWLTBIeVhid2NjQ0FWWTUzb2dxcmlMQThFQmZ4bldzRjcwUQ?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Medical Devices & Supplies - Imaging, Diagnostics Stocks\u2019 Q4 Earnings: Hologic (NASDAQ:HOLX) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOdkl6Ym5HSGVhZUw3TzNlNVFPSjdDQk5NMTVSRW1xVnh3RE5RNU9veVR0TDEtcVdxV3BYelI0bWxCYXgwWmhZQ3ZONUVRdlhjX0ZiMklRVDJQRXN0LXcyVWVnb0E2WTdiRERtZk1pNGpmVHhWbHl5eHJuNnBtTDVPMUluTmRsQUVqYjNlSl8zR3djclh0X2ZIc1gzTlhPanR6ZTJ6R1FB?oc=5", "source_name": "Market source", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "NeuroPace (NPCE) Up 0.9% Since Last Earnings Report: Can It Continue?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxNUHlEQnd4b1lTM2xIRl81TmFtQUxkMlhmd0t4TTJYTFRzSTlxc1JneG43VlFHR1NWcHJUaXpDTUxZdUJkNDI1VXdhcDRRbGpPMDdRaHJybXdhSnZ1b3QtQTBzR1RDS1NONGlqWVVCT1h0VDRFUnhTV1IzTjcyN2d2eHRqVVd3QnFJQ09WckRxZTVYa1U?oc=5", "source_name": "Market source", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Artivion (NYSE:AORT) Vs The Rest Of The Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPaTgxS3dlMlZ5dDZ3dFlGdG9yRWFubkVqMk9yOTN6OEtyemljTWJGYUcxb2pmd2FTNTFKMlhIVGxrdlJsOG5iY1VQaXE4ZmYycTVpRkE0aEJ3QlB5bC10ZXN2dTFYNy0wRWdrNURVUlo5dEMzQklxQ0kwQTRkOXE0UDdTMkRGRWxoQ1ZQeG4tOXNONlR2SkxfZW5ST1B6N3BBeFZZQ3N1UFE?oc=5", "source_name": "Market source", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: CooperCompanies (NASDAQ:COO) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOellVLTAtRXF1dTFacmVLUmptUVpDSkxGX0MtY2hCY2l3ajU4M25SMG95OHdlc1RHN1dmaHZZMF9uQ0o3R1FBa0NzQUtZMjIzMjU1bmttbGZsZUplQkd5Vmd2NEJoQ0NnbVhmVXppdWhiQkdpcGpQVFJVSHRBXy1pbnFJbXI0R2w3MmlvMEdCY2dGYVE4cWY2MENmeEp1ME9mZEFqSDVtdThTMk9kbUhIdXMtR0k?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q4 Earnings: Integer Holdings (NYSE:ITGR) In The Context Of Other Medical Devices & Supplies - Specialty Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAJBVV95cUxNdFRrRlJvM3J3cGJnVEJ6ZndqMnQxWkE4Wm8zTGtPTVc0OTlLN1pwNXIyclNJMFZkcG5qQTRTWThmNm9WN0hKYXBja3N3Y20zSlkxc2JaQlpYTnAyWnpvUVBvR1JWNmVxZGhSYVlYQklMd01GeFBVNGJWOFBWYUkwYmRrM2xrSktiQWpfTkZtNG1HWThNT0tqLUpYek5qcnFWMGE0QV9CaElrMUpfTEhnOC1pS2t1bkE2VVJHdEhWdEtoX2xKNE1MWk1OSlBSNTVZVU83WEpnb3E4aURwQ3ZyZUFDbndpTTZEa0lZRTJvU2VuTDhreXdCQ25iV3Y4YWxENm1xYQ?oc=5", "source_name": "StockStory", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highs And Lows: Abbott Laboratories (NYSE:ABT) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPeVpVN2I3X3lJNXd3TXJmRWV4X0RvRDdYR3l5a1k1SjMxUlhsWHdrUUNuZ1JIaUg4czdhZlA2VDVIallROFFuNmZXcnNzS1d3Vm0wS0tLMmlFVWdkUThsRDZYdTdZV3k3WkRjaUZSMUQ3dkRKYm5ZOVBjMVVBdTRjYQ?oc=5", "source_name": "Market source", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q4 Earnings: Enovis (NYSE:ENOV) In The Context Of Other Medical Devices & Supplies - Specialty Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxNMzBPcXU1cnZKekZnaGlNVk05ZWFTWThNOS0tTlpvQjdaLVZIWlVXUk50NnVoQ0pPWWJpZUpWcVJyVDJMd2RJREVDbEEzTlU5UGhBbWtxWVEyVkdaMTVuNXZpaWFMNTZUQ2d0OW9Rc29kalJRY21naWlHZDBLS3RuZV9wdTdIUQ?oc=5", "source_name": "Market source", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highs And Lows: Baxter (NYSE:BAX) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxOb3BiQVNFREdNblk2QS10b1lhRUtfb05vU2VFZHB5V0hJT0R4NmhwQWRrcFVsR3UwMjZleFV6N2FEelpZVzY3YWFxSWE1cWpLaTFrQVU4NktkQUloUkxaV3ZTVkh6b1ZmaDdMN2ViX1BUNE4xUTNUZFNlR0syVGlZSg?oc=5", "source_name": "Market source", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "NeuroPace (NASDAQ:NPCE) Has Debt But No Earnings; Should You Worry?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-09T08:00:00+00:00", "published_display": "09 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Baird Medical Appoints Mark Saxton as U.S. CEO; Taps Veteran from NeuroPace, Smith + Nephew, and Covidien to Lead Commercial Expansion", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgJBVV95cUxOQ3MxQUtuUVBHNWtMMHlkTnFCNzVsaDA0MGphc2lwelVFMFRCdURSTVd1Y1IwRzNFU0lPbndSRDR4SjQxMXBQb1dibVdNVUtyM1NGekRIVVhtRDhiRUxFeXctLTJjZXNjRFI4NGxDTGZGZWlsSTl2eG1PSGY0Ml9XY1NPUzJLTUQ0R3NING9UTHpoT2ZScVdfT2l1QzlERzNOSmladFlOOHNDV0lLNG9HdTdoWmJ4SlpwbmxGRkZ1V2VOenh3bnpERkY1WmZ5QjZTY3hSVWN4VHc5Q2JHWHBkZWFPVTRSS0ZLS0paZjRxeUgwY1ZrbU0zSzRralJRRTBrM083MF9NMGxvdWZwV25oa3VB?oc=5", "source_name": "PR Newswire", "published_at": "2025-12-03T08:00:00+00:00", "published_display": "03 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Medical Device Maker NeuroPace Sets Q2 Earnings Date: Key Updates Expected for Epilepsy Treatment Leader", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPRHR4LWlndHFPQkVpOEROTkt5M1FMWGRpNGo1TXpYeWt1WHdsSFBCa3FvWUp5NTF4djdiOUZYWUE5Uy1qVmtNeTFUOXR0ZFpIRjdNWGcwTExNSWRYNjdwZXJUMjB3ZnZxTHltZXdDazdla3BXWlpCV203dl9ETndtUElQTmZlcHFnRTRwRmVUSzJLVnA3eUVIeUZvdzlvUEdMR3U0bkVtYVhUOUlpZ1hoVkRrblc2VXItZkFYTG5vUGg?oc=5", "source_name": "Stock Titan", "published_at": "2025-07-29T07:00:00+00:00", "published_display": "29 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NPCE Stock Price and Chart \u2014 NASDAQ:NPCE", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTFA0aFFxLWZySFpnNFRpekZzZlNKLS03NUQ3RXZQbzF1Zkp3cXNHUDZsa2JXeE82WU1mdlhZb2F5ZnhHNm9CNDJvMlZOeWgzby1nTTBGYURKYlVFMEVp?oc=5", "source_name": "TradingView", "published_at": "2021-09-22T07:00:00+00:00", "published_display": "22 Sep 2021 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy NeuroPace (NPCE)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE13S3BscHNaUWFLT3ZuOVpMLTZxcDB1YXR1T3QwS2h3eDBDOXFpUTgyLW55UVVjTU16dV9tWTBpX3AydVhqRG9QXzZKSmo3WTVYZm9TNEItTzJoOWxpNERUVzhNYlFvOGtSRmtXRQ?oc=5", "source_name": "Zacks Investment Research", "published_at": "2021-04-24T23:14:33+00:00", "published_display": "24 Apr 2021 23:14", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroPace (NPCE) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTFBSSWtoWV9OTm1YTGNSMmVzNnhjUTFCM0Jwc2psbkUyZEtLNHRkREtMTC1wWXE2c3ZJWm1nTEVzS0hIa2xzWnQteEo5dHFKM25qNGNtTk1EZHNrUQ?oc=5", "source_name": "MarketBeat", "published_at": "2021-04-23T00:25:53+00:00", "published_display": "23 Apr 2021 00:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mountain View epilepsy device maker NeuroPace's stock jumps 47% in debut", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQcVBXUEJUSkkxVWN1UXRoMFVkUEVncllCZlM2Mml6Zkpjb0hwb0x3a0ktaHFUYmhlNHNJdWd5NTUwVHJZeGVoTlJwZkdxcTZBdlp0SUwzaTY3cVhxUkxZZkRZV1Yya2FSSU1uV3FiRVI3cGFDWFVTOHVJM1dvaF9aTEJ2MkRubDRZOGpmSFY2aWYtOW9NTXlCdUkxQzEwb284aF84VDhyTFk?oc=5", "source_name": "The Business Journals", "published_at": "2021-04-22T07:00:00+00:00", "published_display": "22 Apr 2021 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now", "summary": "NeuroPace (NPCE) stock is recommended for retention due to anticipated growth from its RNS System adoption, expanding referral networks, and AI innovations, with potential long-term benefits from an IGE indication. However, profitability may face near-term pressure from increased", "url": "https://www.tradingview.com/news/zacks:6723c9519094b:0-here-s-why-you-should-retain-neuropace-stock-in-your-portfolio-for-now/", "source_name": "TradingView", "published_at": "2026-07-15T14:13:13", "published_display": "15 Jul 2026 14:13", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroPace (NASDAQ:NPCE) Shares Down 5.8% - What's Next?", "summary": "NeuroPace (NASDAQ:NPCE) shares dropped 5.8% on Tuesday, trading as low as $16.23 on significantly below-average volume. Despite beating recent quarterly earnings and revenue expectations, the company reported negative margins and has a high debt-to-equity ratio of 4.08. Analyst s", "url": "https://www.marketbeat.com/instant-alerts/neuropace-nasdaqnpce-shares-down-58-whats-next-2026-07-14/", "source_name": "MarketBeat", "published_at": "2026-07-14T18:13:10", "published_display": "14 Jul 2026 18:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroPace (NPCE) Proxy filing Summary", "summary": "NeuroPace (NPCE) has scheduled its Annual Meeting for June 5, 2026, to be held virtually, where stockholders of record as of April 9, 2026, will vote on the election of two Class II directors, Lisa Andrade and Scott Huennekens, and the ratification of PricewaterhouseCoopers LLP a", "url": "https://quartr.com/events/neuropace-npce-proxy-filing_ofSSALdK", "source_name": "Quartr", "published_at": "2026-07-10T22:40:39", "published_display": "10 Jul 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroPace, Inc. (NASDAQ:NPCE) Given Consensus Recommendation of \"Moderate Buy\" by Brokerages", "summary": "NeuroPace, Inc. (NASDAQ:NPCE) has received a \"Moderate Buy\" consensus rating from eight analysts, with an average 12-month price target of $18.83. The company recently surpassed quarterly earnings estimates, reporting an EPS of -$0.13 against an expected -$0.19 and revenue slight", "url": "https://www.marketbeat.com/instant-alerts/neuropace-inc-nasdaqnpce-given-consensus-recommendation-of-moderate-buy-by-brokerages-2026-07-10/", "source_name": "MarketBeat", "published_at": "2026-07-10T08:39:39", "published_display": "10 Jul 2026 08:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroPace (NASDAQ:NPCE) Stock Price Up 1.1% - What's Next?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxPSE9ZN18wUDkyTWRWdmZIaldqdjNWYzJucE1ZTE5teGZLSkRUUEF6c2hqOEZWcG1sU3FPSDRfMjFKM2dnaFZIS04wdXBLOEVpMmNqQ01Cek1JSTRIUjB5QWF3VHBlSkZ0Uzdvb2N6YXhCWlhlS3JVa0lMWmpKT2QyU0xRZ0RuX0R3Rm9JTGh4NlU4ajgybEljNk5kNjhPZWd1bFdTQ013?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-10T05:02:47+00:00", "published_display": "10 Jul 2026 05:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "At US$17.80, Is It Time To Put NeuroPace, Inc. (NASDAQ:NPCE) On Your Watch List?", "summary": "NeuroPace, Inc. (NASDAQ:NPCE) has seen a significant share price rise of 39% recently but is currently trading at US$17.80, which is 27% overvalued compared to its intrinsic value of $14.05. Despite this, the company's future outlook appears bright with expected profit growth of ", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-npce/neuropace/news/at-us1780-is-it-time-to-put-neuropace-inc-nasdaqnpce-on-your", "source_name": "Simply Wall Street", "published_at": "2026-07-08T10:11:55", "published_display": "08 Jul 2026 10:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Neuropace, Inc. \u2013 NASDAQ:NPCE", "summary": "This article provides financial information for Neuropace, Inc. (NASDAQ:NPCE), specifically focusing on its forward price-to-earnings ratio. It seems to be a financial data page from TradingView, which lists various financial metrics and resources related to the company. The cont", "url": "https://www.tradingview.com/symbols/NASDAQ-NPCE/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T04:39:18", "published_display": "04 Jul 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NPCE - NeuroPace Inc Short Interest", "summary": "This article provides detailed financial and stock performance data for NeuroPace Inc (NPCE). It covers various metrics including short interest, market capitalization, income, sales, P/E ratios, insider and institutional ownership, and year-over-year growth figures. The data als", "url": "https://finviz.com/stock?t=NPCE&ty=si&ta=1&p=d", "source_name": "Finviz", "published_at": "2026-07-03T08:11:39", "published_display": "03 Jul 2026 08:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NPCE - NeuroPace Inc Website Traffic and Mobile Apps Usage", "summary": "This article provides a comprehensive overview of NeuroPace Inc. (NPCE), a medical device company specializing in epilepsy treatments. It details the company's financial metrics, stock performance, analyst recommendations, and a chronological list of significant news and events, ", "url": "https://finviz.com/stock?t=NPCE&ty=tr", "source_name": "Finviz", "published_at": "2026-07-03T04:39:18", "published_display": "03 Jul 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroPace | 4: Statement of changes in beneficial ownership of securities-Director Fischer Frank M", "summary": "This article announces a statement of changes in beneficial ownership of securities for Director Fischer Frank M at NeuroPace (NPCE), as filed with the SEC on June 6. It also includes extensive disclaimers from Moomoo regarding the informational nature of the content and the risk", "url": "https://www.moomoo.com/news/notice/307480082/neuropace-4-statement-of-changes-in-beneficial-ownership-of-securities", "source_name": "Moomoo", "published_at": "2026-07-02T04:39:18", "published_display": "02 Jul 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price-Driven Insight from (NPCE) for Rule-Based Strategy", "summary": "This article provides a price-driven analysis of Neuropace Inc. (NPCE) using AI models to determine trading strategies. It highlights a strong near-term sentiment that could lead to a neutral mid-term and positive long-term bias, and outlines specific institutional trading strate", "url": "https://news.stocktradersdaily.com/news_release/11/Price-Driven_Insight_from_NPCE_for_Rule-Based_Strategy_062826121803_1782620283.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-28T00:10:14", "published_display": "28 Jun 2026 00:10", "sentiment": "positive", "sentiment_pct": 68, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroPace, Inc. (NPCE) Reveals FDA Approval of ECoG Assistant\u2122", "summary": "NeuroPace, Inc. (NASDAQ:NPCE) announced FDA approval for its ECoG Assistant\u2122, an AI-driven tool designed to enhance epilepsy care by analyzing long-term intracranial EEG data. The technology, built on extensive epileptologist-labeled records, aims to improve efficiency in data re", "url": "https://www.insidermonkey.com/blog/neuropace-inc-npce-reveals-fda-approval-of-ecog-assistant-1790336/", "source_name": "Insider Monkey", "published_at": "2026-06-27T11:31:00", "published_display": "27 Jun 2026 11:31", "sentiment": "positive", "sentiment_pct": 90, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroPace, Inc. Actuals & Estimates (NASDAQ:NPCE)", "summary": "This article provides an overview of NeuroPace, Inc. (NASDAQ: NPCE) stock, including its current price, market capitalization, historical highs and lows, and analyst forecasts. It also details recent financial performance, such as earnings per share and revenue for past quarters,", "url": "https://www.tradingview.com/symbols/NASDAQ-NPCE/forecast-actuals-and-estimates/?category=cash_flow", "source_name": "TradingView", "published_at": "2026-06-26T02:09:55", "published_display": "26 Jun 2026 02:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroPace (NPCE) CMO has shares withheld to cover RSU tax bill", "summary": "NeuroPace Inc.'s Chief Medical Officer, Martha Morrell, had 335 shares of common stock withheld on June 24, 2026, to cover tax obligations related to a restricted stock unit vesting. These shares were disposed of at $16.22 per share. Following this transaction, Morrell directly h", "url": "https://www.stocktitan.net/sec-filings/NPCE/form-4-neuro-pace-inc-insider-trading-activity-5979203ed972.html", "source_name": "Stock Titan", "published_at": "2026-06-25T20:09:21", "published_display": "25 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NPCE Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides an overview of Neuropace, Inc. (NPCE) stock, including its current price, analyst forecasts, and recent financial performance. It highlights that 8 analysts offer 1-year price targets, with a max estimate of $22.00 and a min estimate of $18.00. The company's", "url": "https://www.tradingview.com/symbols/NASDAQ-NPCE/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T17:09:22", "published_display": "25 Jun 2026 17:09", "sentiment": "positive", "sentiment_pct": 63, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Neuropace Inc For: 22 June By Investing.com", "summary": "This article provides details about a Form 4 filing for Neuropace Inc. on June 22 and mentions the company's stock symbol NPCE, which saw a slight decrease. It is a very brief report, likely indicating an insider transaction or change in ownership, without providing further speci", "url": "https://ng.investing.com/news/stock-market-news/form-4-neuropace-inc-for-22-june-93CH-2568689", "source_name": "Investing.com Nigeria", "published_at": "2026-06-22T21:38:00", "published_display": "22 Jun 2026 21:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroPace (NPCE) director granted 789 shares as quarterly fee award", "summary": "NeuroPace director Uri Geiger was awarded 789 shares of common stock at $15.63 per share as a quarterly fee, in lieu of a cash retainer, under the company's non-employee director compensation policy. Following this award, Geiger directly holds 18,537 NeuroPace shares, with an add", "url": "https://www.stocktitan.net/sec-filings/NPCE/form-4-neuro-pace-inc-insider-trading-activity-725f3038cc28.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:39:33", "published_display": "22 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroPace (NPCE) director Rakhi Kumar awarded 989 shares as quarterly retainer", "summary": "NeuroPace Inc. director Rakhi Kumar was granted 989 common shares as a quarterly retainer, valued at $15.63 per share. This stock award is part of the company's non-employee director compensation policy and increases Kumar's direct holdings to 23,039 NeuroPace common shares. The ", "url": "https://www.stocktitan.net/sec-filings/NPCE/form-4-neuro-pace-inc-insider-trading-activity-11875424d20a.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:39:33", "published_display": "22 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] NeuroPace Inc Insider Trading Activity", "summary": "NeuroPace Inc. director Frank M. Fischer reported the acquisition of 1,467 shares of Common Stock on June 19, 2026, as detailed in a recent Form 4 filing. These shares were awarded as part of the company's non-employee director compensation policy, given in lieu of quarterly cash", "url": "https://www.stocktitan.net/sec-filings/NPCE/form-4-neuro-pace-inc-insider-trading-activity-d4f63e662224.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:39:33", "published_display": "22 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroPace, Inc.(NasdaqGM:NPCE) added to S&P Healthcare Equipment Select Industry Index", "summary": "NeuroPace, Inc. (NasdaqGM:NPCE), a medical device company specializing in epilepsy treatment, has been added to the S&P Healthcare Equipment Select Industry Index. This news follows recent company updates, including FDA approval for its ECoG Assistant and the submission of a next", "url": "https://www.marketscreener.com/news/neuropace-inc-nasdaqgm-npce-added-to-s-p-healthcare-equipment-select-industry-index-ce7f5cd3d88afe21", "source_name": "www.marketscreener.com", "published_at": "2026-06-22T01:10:38", "published_display": "22 Jun 2026 01:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuropace Inc (NPCE) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Neuropace Inc (NPCE) has a weak financial health score of 6.53, ranking 150 out of 203 in its industry, with average operating efficiency. Its latest quarterly revenue saw a 2.02% year-over-year decrease to $22.07 million, and net profit also fell by 1.52% year-over-year. Key fin", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-npce/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T10:39:25", "published_display": "18 Jun 2026 10:39", "sentiment": "negative", "sentiment_pct": 30, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuropace Inc (NPCE) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Neuropace Inc (NPCE), detailing its price momentum score of 6.58 and its current trading range between a resistance level of $16.91 and a support level of $14.14. It examines various technical indicators, such as MACD, RSI, and moving", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-npce/technical", "source_name": "TradingKey", "published_at": "2026-06-18T03:40:13", "published_display": "18 Jun 2026 03:40", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuropace Inc (NPCE) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Neuropace Inc (NPCE), noting its current valuation score is 9.40, ranking 21st in its industry. It highlights the company's P/E ratio of -23.50, which is significantly below its recent high. The report also states that relevant P/B, P", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-npce/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T02:40:50", "published_display": "18 Jun 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuropace Inc (NPCE) Institutional Confidence", "summary": "Neuropace Inc (NPCE) has an institutional shareholding score of 10.00, placing it first in the Healthcare Equipment & Supplies industry. Institutional investors hold 99.26% of shares, a 7.21% increase quarter-over-quarter. James Simons is the largest institutional shareholder, ho", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-npce/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T02:40:13", "published_display": "18 Jun 2026 02:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuropace Inc (NPCE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article focuses on the revenue breakdown for NeuroPace Inc (NPCE), indicating that relevant data for business segments and regional profit contributions have not yet been disclosed by the company. It briefly presents the company's United States revenue at $99.99 million with", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-npce/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T01:40:13", "published_display": "18 Jun 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(NPCE) Price Dynamics and Execution-Aware Positioning", "summary": "This article analyzes Neuropace Inc. (NPCE) stock dynamics, highlighting weak near and mid-term sentiment but a strong long-term outlook. It presents AI-generated trading strategies including position trading, momentum breakout, and risk hedging, with specific entry points, targe", "url": "https://news.stocktradersdaily.com/news_release/12/NPCE_Price_Dynamics_and_Execution-Aware_Positioning_061626110601_1781665561.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-16T23:10:59", "published_display": "16 Jun 2026 23:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuropace Inc (NPCE) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Neuropace Inc (NPCE), highlighting its current earnings forecast score of 8.50 and an average analyst price target of $18.00. Analysts largely recommend a \"Buy\" for NPCE, with expectations for future revenue and EPS also detailed. Th", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-npce/earnings", "source_name": "TradingKey", "published_at": "2026-06-16T22:10:32", "published_display": "16 Jun 2026 22:10", "sentiment": "positive", "sentiment_pct": 68, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroPace (NPCE) down 0.6% since last earnings report: Can it rebound?", "summary": "This article discusses the recent performance of NeuroPace (NPCE) stock, which has dropped 0.6% since its last earnings report. It raises the question of whether the stock can rebound from this decline. The content of the article would likely delve into factors influencing NPCE's", "url": "https://www.msn.com/en-us/money/topstocks/neuropace-npce-down-0-6-since-last-earnings-report-can-it-rebound/ar-AA25p2rH", "source_name": "MSN", "published_at": "2026-06-15T16:39:39", "published_display": "15 Jun 2026 16:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts Believe NeuroPace (NPCE) Could Rally 27.88%: Here's is How to Trade", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/wall-street-analysts-believe-neuropace-135503665.html", "source_name": "Zacks", "published_at": "2026-06-15T13:55:03+00:00", "published_display": "15 Jun 2026 13:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroPace Inc RNS System gains favor for targeted seizure interruption", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxNNmREdzhmckdRMVJWYldMVGlyZlM5U2pMYkxFZHhNV2RDck9lWGt0cDdJbUlqZFJjWER2TDMwbDJmM05PbzE5NnBWb0MwakdYTnVEdXprNXFJV21ySlhwRm9yQ0lqZ19YMVdnUlVDZlM5MUd3Wm1YcU5lV1Y3UmlUak5IbEM?oc=5", "source_name": "Traders Union", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why You Should Add NeuroPace Stock to Your Portfolio Now", "summary": "NeuroPace, Inc. (NPCE) is poised for significant growth, driven by the strong adoption of its RNS System, expanding referral networks, and AI-driven innovations aimed at improving efficiency in epilepsy treatment. The potential FDA approval for idiopathic generalized epilepsy (IG", "url": "https://www.tradingview.com/news/zacks:1b6ea4907094b:0-here-s-why-you-should-add-neuropace-stock-to-your-portfolio-now/", "source_name": "TradingView", "published_at": "2026-06-10T14:39:03", "published_display": "10 Jun 2026 14:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroPace, Inc. Files Form 8-K Reporting 2026 Annual Meeting Results and Company Information", "summary": "NeuroPace, Inc. filed Form 8-K to report the results of its 2026 Annual Meeting, held virtually on June 5, 2026. Shareholders re-elected two Class II directors and ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm, showing strong support for", "url": "https://www.minichart.com.sg/2026/06/09/neuropace-inc-files-form-8-k-reporting-2026-annual-meeting-results-and-company-information/", "source_name": "Minichart", "published_at": "2026-06-09T17:49:42", "published_display": "09 Jun 2026 17:49", "sentiment": "positive", "sentiment_pct": 60, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The NeuroPace (NPCE) Investment Story Is Shifting Without A New Analyst Price Target", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQVXBlemUxQm5vTlJCQ28xNFZNRTZpZDNPMmFNbXpPTTBFNGFoak1JQUFybUtQMnF4MFBIU1VDMDZ3NFljbHJjUHNfX1lsV3lkSHhVbGhuanRNbzdlckNRODhwLTFiOGpuMDZsYzNockR1cGxiejdGZEhuMm9RT3dBcWlfbldiZ1RSVHZHYy1udDA2emlRRTBzOU5JY2N3NmcySmlqUm9yUFU?oc=5", "source_name": "Market source", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroPace Says US FDA Approves ECoG Assistant for Improving Epilepsy Outcomes", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/neuropace-says-us-fda-approves-124357999.html", "source_name": "MT Newswires", "published_at": "2026-05-29T12:43:57+00:00", "published_display": "29 May 2026 12:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NPCE Explains How NeuroPace's RNS System Makes Money", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxONGlfX0dLM2RwM3JGcHpSYV9lUUxDemVmT1lCWFRQbE52U0RUWEFnZ3ZoZHdyemszeFZ1dzJvekZZNFJESG5wQTJRUHd1MmJVNVZDZnMwZ0NKdlVia0R0clJZWUk1Vll0ZWdzd3lvRW5oQ09nbjNVOGd5a0lPX2M4YlZxaE5hc0c1ZklGU2MzTF9FNXdPbTh6ZlJXSmRCV1FLYU9zeWNQZw?oc=5", "source_name": "Market source", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroPace NPCE and the Next Wave of AI-Driven Epilepsy Care", "summary": "", "url": "https://news.google.com/rss/articles/CBMif0FVX3lxTFBDWE9XVi1KdlJpVzIzU0gzWGgyc1hLWDhTQlJybmpyWXpFTFFBLUVJbjk3R0QyM1o2VWxnYUxoc1BJTnhhcmZrQlRSS0RTdEo0R2NvWUJLZ1JxWG9GX1BRNlg4d3FaRER1dV90SWtDQ0lXU2FhWDNUb2thbXB0TDg?oc=5", "source_name": "qz.com", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroPace, Inc. (NASDAQ:NPCE) First-Quarter Results: Here's What Analysts Are Forecasting For This Year", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQamNzQTM2WlNEaVBlNnpNZUsyM3hQWGVyWnhhR1hZbU80ek04SU5PYlI2clNQOGJnZ05LZGNXenZEV3puT2FPT0otdko4eExiblQ5YVhQZy1ETDRVQW53Vks0TzRIakxMc2ZKVVZINFI5dDRnbkkzRzRrdFFrRkttTGFYd1E5MkQyMTRBTE9pYWVDQy1wdkg0WVNPdk8?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroPace (NPCE) Moves 6.3% Higher: Will This Strength Last?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiekFVX3lxTE9aR2d1NUY1UWJDdzNaeFJLMld3N19ZNDRwN01rZ3hNRFdXOGNVYlg5cFhXSFQtRzBLdmZQQThCZXUyTmduLXBfSF9IelN4ZHAydEFDelQ5WWlWdElpd3ZqVUQzbW9pd1ZUMTEwLTZDWnRBQmVLNXJQS25R?oc=5", "source_name": "qz.com", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroPace (NPCE) Up 0.9% Since Last Earnings Report: Can It Continue?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxNUHlEQnd4b1lTM2xIRl81TmFtQUxkMlhmd0t4TTJYTFRzSTlxc1JneG43VlFHR1NWcHJUaXpDTUxZdUJkNDI1VXdhcDRRbGpPMDdRaHJybXdhSnZ1b3QtQTBzR1RDS1NONGlqWVVCT1h0VDRFUnhTV1IzTjcyN2d2eHRqVVd3QnFJQ09WckRxZTVYa1U?oc=5", "source_name": "Market source", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroPace (NASDAQ:NPCE) Has Debt But No Earnings; Should You Worry?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-09T08:00:00+00:00", "published_display": "09 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Baird Medical Appoints Mark Saxton as U.S. CEO; Taps Veteran from NeuroPace, Smith + Nephew, and Covidien to Lead Commercial Expansion", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgJBVV95cUxOQ3MxQUtuUVBHNWtMMHlkTnFCNzVsaDA0MGphc2lwelVFMFRCdURSTVd1Y1IwRzNFU0lPbndSRDR4SjQxMXBQb1dibVdNVUtyM1NGekRIVVhtRDhiRUxFeXctLTJjZXNjRFI4NGxDTGZGZWlsSTl2eG1PSGY0Ml9XY1NPUzJLTUQ0R3NING9UTHpoT2ZScVdfT2l1QzlERzNOSmladFlOOHNDV0lLNG9HdTdoWmJ4SlpwbmxGRkZ1V2VOenh3bnpERkY1WmZ5QjZTY3hSVWN4VHc5Q2JHWHBkZWFPVTRSS0ZLS0paZjRxeUgwY1ZrbU0zSzRralJRRTBrM083MF9NMGxvdWZwV25oa3VB?oc=5", "source_name": "PR Newswire", "published_at": "2025-12-03T08:00:00+00:00", "published_display": "03 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Medical Device Maker NeuroPace Sets Q2 Earnings Date: Key Updates Expected for Epilepsy Treatment Leader", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPRHR4LWlndHFPQkVpOEROTkt5M1FMWGRpNGo1TXpYeWt1WHdsSFBCa3FvWUp5NTF4djdiOUZYWUE5Uy1qVmtNeTFUOXR0ZFpIRjdNWGcwTExNSWRYNjdwZXJUMjB3ZnZxTHltZXdDazdla3BXWlpCV203dl9ETndtUElQTmZlcHFnRTRwRmVUSzJLVnA3eUVIeUZvdzlvUEdMR3U0bkVtYVhUOUlpZ1hoVkRrblc2VXItZkFYTG5vUGg?oc=5", "source_name": "Stock Titan", "published_at": "2025-07-29T07:00:00+00:00", "published_display": "29 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NPCE Stock Price and Chart \u2014 NASDAQ:NPCE", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTFA0aFFxLWZySFpnNFRpekZzZlNKLS03NUQ3RXZQbzF1Zkp3cXNHUDZsa2JXeE82WU1mdlhZb2F5ZnhHNm9CNDJvMlZOeWgzby1nTTBGYURKYlVFMEVp?oc=5", "source_name": "TradingView", "published_at": "2021-09-22T07:00:00+00:00", "published_display": "22 Sep 2021 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy NeuroPace (NPCE)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE13S3BscHNaUWFLT3ZuOVpMLTZxcDB1YXR1T3QwS2h3eDBDOXFpUTgyLW55UVVjTU16dV9tWTBpX3AydVhqRG9QXzZKSmo3WTVYZm9TNEItTzJoOWxpNERUVzhNYlFvOGtSRmtXRQ?oc=5", "source_name": "Zacks Investment Research", "published_at": "2021-04-24T23:14:33+00:00", "published_display": "24 Apr 2021 23:14", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroPace (NPCE) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTFBSSWtoWV9OTm1YTGNSMmVzNnhjUTFCM0Jwc2psbkUyZEtLNHRkREtMTC1wWXE2c3ZJWm1nTEVzS0hIa2xzWnQteEo5dHFKM25qNGNtTk1EZHNrUQ?oc=5", "source_name": "MarketBeat", "published_at": "2021-04-23T00:25:53+00:00", "published_display": "23 Apr 2021 00:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mountain View epilepsy device maker NeuroPace's stock jumps 47% in debut", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQcVBXUEJUSkkxVWN1UXRoMFVkUEVncllCZlM2Mml6Zkpjb0hwb0x3a0ktaHFUYmhlNHNJdWd5NTUwVHJZeGVoTlJwZkdxcTZBdlp0SUwzaTY3cVhxUkxZZkRZV1Yya2FSSU1uV3FiRVI3cGFDWFVTOHVJM1dvaF9aTEJ2MkRubDRZOGpmSFY2aWYtOW9NTXlCdUkxQzEwb284aF84VDhyTFk?oc=5", "source_name": "The Business Journals", "published_at": "2021-04-22T07:00:00+00:00", "published_display": "22 Apr 2021 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Reflecting On Medical Devices & Supplies - Specialty Stocks\u2019 Q1 Earnings: Integer Holdings (NYSE:ITGR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNUFd1SUpRcWlCdEFjU1YzNTZkdjBfRkwyY2lBYjh1ZXZlZTlyVlpWSWx1bExvckFrNHNhUEdVTGNFWUxaMkVDZUV2c2hPS1h2YVhNSHNsVzFYNUFrNHBnRVM1STRsa2Zmb0VXeEQ4UFRGNDBOWXZfWVU5VFUyQ3JZZm9KamZMWXVDSEtNMWwyVktpaEZfRjVNU1BYaWJ3NnpNUmRyMEpsSzBXdw?oc=5", "source_name": "Market source", "published_at": "2026-07-14T18:07:11+00:00", "published_display": "14 Jul 2026 18:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks Q1 Earnings: ICU Medical (NASDAQ:ICUI) Firing on All Cylinders", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAJBVV95cUxQLWl0NWl5MFJhUXFSN0pzSW1sVzJVb21XVml0X0doQnd5eDVUQmVqeFZWSmNmdlZaV2pfbFk3UEl3RXlqZ05pckozR0dnNHNEUlpTa2FPYWc1Z3Q0Y2tXYTljZUlQRkVZNzY2Sl9yRksyUDJkNVQzSTBuLW9uMnI5bzBfTTJGdDUzd25DN3dDSmhwWnpGVXZRVVM2Uy1zMnp4STZ1RGdZZkRpZ21Pb2xtWjRSTk1kc2JrT28wTG81NDV1M2tWaVdrOXBQdVZSTExiTVEzMXpqRnJWWi0xcEdMYVFILXZXbXZVZl9GRm12aTl5OGk4X1dSVjVyU2FIVFpubk1YNm5fQll0MVZqRTZpTA?oc=5", "source_name": "StockStory", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q1 Earnings Review: Medical Devices & Supplies - Diversified Stocks Led by Baxter (NYSE:BAX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNYjhBT3BjMWFVU1FFUUFub0d6QUVEUTdwWFVMRG5fN2dHSnIxTXQwMWU1aElKaEV1a2dYLTFHMlBzMVFTZEtaX0xRRDFhZDl1WFdDYWF2RDZxOG9SRUtycmZacTRzM2FaaEU3OS1GZ2taLWtSMjZ4enhVNHRvdzJsanp4cEhNcGI1dllTOUplWUUtNjRlRm85MlFEVWxSYUV2d243QVd3?oc=5", "source_name": "Market source", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Medical Devices & Supplies - Specialty Q4 Earnings: Globus Medical (NYSE:GMED) is the Best in the Biz", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNcDFMNmtOVk5PVFM1YzMyVWhyS3dwY0dMVE5BUng5U1JoOFRQMXNFRGxTMmlBRUV0bENRSWFXTDFZOXBQQkNZT0FOWDdISjRCcU9pRV9aNHBwUVBuZkVEV3g1dklVY19KOE9iWUNpNUtMS2NuOEcxMlQtNU8ydURybEdkNVoxZThWLTBIeVhid2NjQ0FWWTUzb2dxcmlMQThFQmZ4bldzRjcwUQ?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Medical Devices & Supplies - Imaging, Diagnostics Stocks\u2019 Q4 Earnings: Hologic (NASDAQ:HOLX) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOdkl6Ym5HSGVhZUw3TzNlNVFPSjdDQk5NMTVSRW1xVnh3RE5RNU9veVR0TDEtcVdxV3BYelI0bWxCYXgwWmhZQ3ZONUVRdlhjX0ZiMklRVDJQRXN0LXcyVWVnb0E2WTdiRERtZk1pNGpmVHhWbHl5eHJuNnBtTDVPMUluTmRsQUVqYjNlSl8zR3djclh0X2ZIc1gzTlhPanR6ZTJ6R1FB?oc=5", "source_name": "Market source", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Artivion (NYSE:AORT) Vs The Rest Of The Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPaTgxS3dlMlZ5dDZ3dFlGdG9yRWFubkVqMk9yOTN6OEtyemljTWJGYUcxb2pmd2FTNTFKMlhIVGxrdlJsOG5iY1VQaXE4ZmYycTVpRkE0aEJ3QlB5bC10ZXN2dTFYNy0wRWdrNURVUlo5dEMzQklxQ0kwQTRkOXE0UDdTMkRGRWxoQ1ZQeG4tOXNONlR2SkxfZW5ST1B6N3BBeFZZQ3N1UFE?oc=5", "source_name": "Market source", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: CooperCompanies (NASDAQ:COO) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOellVLTAtRXF1dTFacmVLUmptUVpDSkxGX0MtY2hCY2l3ajU4M25SMG95OHdlc1RHN1dmaHZZMF9uQ0o3R1FBa0NzQUtZMjIzMjU1bmttbGZsZUplQkd5Vmd2NEJoQ0NnbVhmVXppdWhiQkdpcGpQVFJVSHRBXy1pbnFJbXI0R2w3MmlvMEdCY2dGYVE4cWY2MENmeEp1ME9mZEFqSDVtdThTMk9kbUhIdXMtR0k?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q4 Earnings: Integer Holdings (NYSE:ITGR) In The Context Of Other Medical Devices & Supplies - Specialty Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAJBVV95cUxNdFRrRlJvM3J3cGJnVEJ6ZndqMnQxWkE4Wm8zTGtPTVc0OTlLN1pwNXIyclNJMFZkcG5qQTRTWThmNm9WN0hKYXBja3N3Y20zSlkxc2JaQlpYTnAyWnpvUVBvR1JWNmVxZGhSYVlYQklMd01GeFBVNGJWOFBWYUkwYmRrM2xrSktiQWpfTkZtNG1HWThNT0tqLUpYek5qcnFWMGE0QV9CaElrMUpfTEhnOC1pS2t1bkE2VVJHdEhWdEtoX2xKNE1MWk1OSlBSNTVZVU83WEpnb3E4aURwQ3ZyZUFDbndpTTZEa0lZRTJvU2VuTDhreXdCQ25iV3Y4YWxENm1xYQ?oc=5", "source_name": "StockStory", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highs And Lows: Abbott Laboratories (NYSE:ABT) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPeVpVN2I3X3lJNXd3TXJmRWV4X0RvRDdYR3l5a1k1SjMxUlhsWHdrUUNuZ1JIaUg4czdhZlA2VDVIallROFFuNmZXcnNzS1d3Vm0wS0tLMmlFVWdkUThsRDZYdTdZV3k3WkRjaUZSMUQ3dkRKYm5ZOVBjMVVBdTRjYQ?oc=5", "source_name": "Market source", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q4 Earnings: Enovis (NYSE:ENOV) In The Context Of Other Medical Devices & Supplies - Specialty Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxNMzBPcXU1cnZKekZnaGlNVk05ZWFTWThNOS0tTlpvQjdaLVZIWlVXUk50NnVoQ0pPWWJpZUpWcVJyVDJMd2RJREVDbEEzTlU5UGhBbWtxWVEyVkdaMTVuNXZpaWFMNTZUQ2d0OW9Rc29kalJRY21naWlHZDBLS3RuZV9wdTdIUQ?oc=5", "source_name": "Market source", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highs And Lows: Baxter (NYSE:BAX) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxOb3BiQVNFREdNblk2QS10b1lhRUtfb05vU2VFZHB5V0hJT0R4NmhwQWRrcFVsR3UwMjZleFV6N2FEelpZVzY3YWFxSWE1cWpLaTFrQVU4NktkQUloUkxaV3ZTVkh6b1ZmaDdMN2ViX1BUNE4xUTNUZFNlR0syVGlZSg?oc=5", "source_name": "Market source", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 92, "total_relevant": 57, "sentiment_summary": {"positive": 16, "negative": 3, "neutral": 38, "score": 55, "total": 57, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 75, "events": [{"event": "general", "label": "Market update", "weight": 13.35, "count": 23}, {"event": "earnings", "label": "Earnings", "weight": 12.24, "count": 25}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.65, "count": 3}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 16, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 17.11, "latest_week": "2026-07-10", "one_week_move": 6.0, "four_week_move": 9.4, "twelve_week_move": 5.7, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.220153, "market_dynamics_buy_signal": false, "relative_strength": 7.823147, "fair_value_gap": 51.7, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 52.9346, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+6.0% over one week, +9.4% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 62, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 13}, {"label": "TradingView", "count": 6}, {"label": "TradingKey", "count": 6}, {"label": "Stock Titan", "count": 5}, {"label": "MarketBeat", "count": 4}, {"label": "Finviz", "count": 2}, {"label": "Stock Traders Daily", "count": 2}, {"label": "StockStory", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 46}, {"label": "Industry context", "count": 11}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 25}, {"label": "Market update", "count": 23}, {"label": "Analyst action", "count": 3}, {"label": "Regulatory and legal", "count": 3}, {"label": "Balance sheet", "count": 1}, {"label": "Deals and strategy", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "55/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "75/100 classification confidence."}, {"label": "Company focus", "value": "46", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+6.0% over one week, +9.4% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now"}], "updated_at": "2026-07-17T07:59:52.065486+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}